Search PubMed⌕ Search

Biomedical subjects

V Lukić

Publications and source records attributed to V Lukić.

At least 19 recordsLinked to original sources
PubMed1993

Effect of fentanyl, ketamine and thalamonal on some biochemical parameters in ethanol-treated and untreated dogs.

The effects of fentanyl, ketamine and thalamonal on some biochemical parameters of ethanol-treated and untreated dogs, were studied. The study was carried out on mongrel dogs. The animals were divided into two main groups: one which had free access to food and to 12% (v/v) ethanol, instead of water, and a control group which had food and water ad libitum. The animals in both groups were exposed to the action of anaesthetics for 3 h. The results show that, under the given experimental conditions, the anaesthetics did not significantly change the investigated parameters of blood and liver, either in ethanol-treated or untreated dogs. However, the action of ethanol caused remarkable changes in almost all the investigated parameters. An increased content of cytochrome P450 caused by the action of ethanol suggests possible changes in the metabolism of anaesthetics, which should be of concern to anaesthetists when dealing with patients potentially intoxicated with ethanol.

Anesthetics↗
PubMedDate not supplied

The in vitro and in vivo biotransformation of N-deacetyl-N-formylcolchicine.

The major pathway of metabolic transformation of N-deacetyl-N-formylcolchicine is the oxidative cytochrome P450 dependent O-demethylation of substituents in the aromatic ring A and tropolone ring C. It was found that O-demethylation (both, in vitro and in vivo) takes place predominantly in the aromatic ring, especially at position 2.

Animals↗
PubMedDate not supplied

Mitoxantrone, 5-fluorouracil and low-dose leucovorin in doxorubicin-resistant advanced breast cancer patients: a phase II study.

AIM: Twenty-two anthracycline-resistant advanced breast cancer patients were entered from June 1995 till November 1997 in a phase II study to assess the activity and tolerability of second-line chemotherapy consisting of mitoxantrone, 5-fluorouracil and low-dose leucovorin. STUDY DESIGN: Patients were eligible if they failed to respond to doxorubicin-containing chemotherapy, given as first-line chemotherapy for metastatic disease. Treatment consisted of mitoxantrone, 12 mg/m2 iv infusion on day 1, and leucovorin, 50 mg iv 1 hr before 5-fluorouracil, 350 mg/m2 iv infusion on days 1-3, every three weeks. RESULTS: Nineteen patients were eligible for response, 2 refused further therapy after 2 cycles, and 1 was excluded because grade 3 myelotoxicity developed during the first cycle. Partial remission of 15 months duration occurred in 1 patient, in 7/19 women disease remained stable with a median duration of 11 months (range, 5-24), and 11/19 patients experienced progressive disease. Median time to disease progression was 2 months (range, 0-17), and median survival was 8 months (range, 0-24). Toxicity was generally mild and acceptable. One patient was excluded because of grade 3 granulocytopenia and thrombocytopenia, and one due to cardiotoxicity assessed by the drop of left ventricular ejection fraction to more than 20% below the initial value. CONCLUSIONS: In spite of the very low objective response rate, almost one-fourth of our anthracycline-resistant patients achieved a disease stabilization of 27 weeks duration during mitoxantrone-based second-line chemotherapy. Hence, mitoxantrone in combination with 5-fluorouracil, especially continuous infusion, should be further investigated in this setting, particularly if new and expensive drugs, considered the most active, are not readily available.

Adult↗